Where to Buy Sermorelin Online: How the Prescription Route Works

Growth-hormone-releasing hormone, GHRH, is a 44-amino-acid peptide made in the hypothalamus whose job is to tell the pituitary to release growth hormone. Sermorelin is the first 29 of those 44 amino acids with an amide on the end — GHRH(1-29)-NH2 in the literature — the shortest fragment of the native hormone that keeps its full activity. It binds the GHRH receptor on pituitary somatotrophs, the cells that make and store growth hormone, and triggers release of a pulse. Human studies describe this as fast: in the Khorram, Laughlin and Yen trial in the Journal of Clinical Endocrinology and Metabolism in 1997, a nightly subcutaneous dose of a GHRH(1-29) analogue produced a measurable rise in growth hormone within minutes, lasting a couple of hours.

That is the whole clinical argument for sermorelin. Because the pituitary does the releasing, the body's feedback regulation stays in place: somatostatin still inhibits release, and rising IGF-1 still feeds back on the hypothalamus and pituitary. Injected growth hormone bypasses that loop and replaces the pulsatile pattern with a sustained elevation; sermorelin works through the loop and produces a pulse followed by a return to baseline. National Institute on Aging work in the same journal in 1992 described GHRH(1-29) in healthy men in their late sixties raising the amplitude of their growth hormone peaks toward those of young men while keeping the pulsatile pattern intact.

Most of what growth hormone does in adults it does through insulin-like growth factor 1, made in the liver. A single growth hormone sample is nearly meaningless because of pulsatility; IGF-1 integrates the previous days' secretion, which is why it is the blood test a prescriber orders before sermorelin and rechecks on it. The 1997 Khorram trial reported IGF-1 rising within two weeks of nightly dosing in adults aged 55 to 71.

It is not HGH, and a provider selling it as "HGH without the prescription" has the relationship backwards: sermorelin is a prescription medication with a different mechanism. It contains no growth hormone; it asks the pituitary to release what it makes, and if the pituitary cannot respond it does nothing, which is why it once worked as a diagnostic test. It is not an anabolic steroid and not a weight-loss drug. See peptides vs HGH and the full reference, what sermorelin is.

The assessment is free and goes to a physician licensed in your state. For sermorelin the questions that carry the most weight are cancer history; diabetes, prediabetes or a previous high HbA1c; thyroid disease; every medication you take, because glucocorticoids, thyroid medication, insulin and other diabetes drugs all interact with the growth hormone axis; and what you are actually trying to change.

A physician reads the intake, not an algorithm, and three outcomes are possible: a request for labs, a decline with a reason, or a prescription. A decline is a legitimate outcome and it is refunded; common reasons are a cancer history that has not been discussed with an oncologist, uncontrolled diabetes, or a presentation that points to thyroid or testosterone rather than growth hormone. Recent bloodwork from elsewhere can be uploaded rather than repeated.

The reviewed directions for sermorelin are to inject 0.25 mL, which is 25 units on a U-100 insulin syringe, subcutaneously Monday through Friday nights. Night because the pituitary's largest natural pulse occurs in the first hours of deep sleep; five nights rather than seven because prescribers commonly build in two nights off each week. Your own directions are what apply and they are printed on your medication.

The prescription goes to a state-licensed, FDA-registered compounding pharmacy that prepares sermorelin in solution to the prescribed strength under USP sterile compounding standards and ships it refrigerated in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. One vial per fill, always — a 28-day supply, not a stockpile.

You can message the prescriber with dose questions or side effects. IGF-1 is usually rechecked in the first couple of months rather than assumed, alongside glucose markers where there was any concern at baseline, and the 28-day refill schedule exists partly so the physician sees the pattern over time. Treatment is long-term and continues month to month until you and your physician decide otherwise.

A legitimate provider tells you a physician licensed in your state will review your intake, and the physician's name appears on your prescription and on the pharmacy label. Every state medical board runs a public licence lookup. A provider that will not name the prescriber, or whose "medical review" is a checkbox, is not offering a medical service.

You should know, before you pay, which pharmacy will fill the prescription, and it should be a compounding pharmacy licensed by its own state board and registered with the FDA. Pepti's pharmacy partners and how they are chosen are described on /quality.

A provider that stands behind its product can show you third-party testing of the finished, dispensed medication: identity confirmed, potency within the labelled strength, sterility and endotoxin results, with a batch identifier that matches what shipped. Sermorelin results are published at /quality/lab-results#sermorelin.

A pharmacy label carries your name, the drug and strength, the directions, the pharmacy's name and address, the prescriber's name, and a beyond-use date; a vial that arrives with "not for human consumption" is a research product, whatever the website said. And because sermorelin has a follow-up built into it, the IGF-1 recheck, a provider that cannot be reached after the sale has skipped half the medicine.

The starting point for most people who arrive asking for sermorelin specifically: a single GHRH analogue, dosed at night, followed with IGF-1, and the simplest product to interpret because if IGF-1 moves there is only one thing that moved it. The same medication comes as a pre-filled cartridge for the reusable pepti Pen, dosed in clicks rather than drawn with a syringe; the Pen removes the draw step and costs more, and it is not clinically better.

GHRH-receptor and ghrelin-receptor agonists reach the somatotroph through different doors, and combining them is the usual clinical approach. Ipamorelin + Sermorelin keeps sermorelin as the GHRH side and adds ipamorelin, described in a 1998 paper in the European Journal of Endocrinology as the first selective growth hormone secretagogue, releasing growth hormone without a meaningful rise in cortisol or prolactin at the doses studied. A 2018 review in Sexual Medicine Reviews covers the class. Neither combination has adult outcome trials.

The most commonly prescribed pairing in this category swaps sermorelin for CJC-1295, a longer-acting GHRH analogue. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported prolonged stimulation of growth hormone and IGF-1 in healthy adults after CJC-1295, and a companion paper the same year reported growth hormone pulsatility persisting during continuous stimulation with it. The comparison with sermorelin is in CJC-1295 vs sermorelin; CJC-1295 / Ipamorelin is the product.

CJC-1295 / Ipamorelin / Sermorelin puts both GHRH analogues and ipamorelin in one Pen cartridge, for someone whose physician wants the longer-acting GHRH signal alongside the shorter one.

Tesamorelin is the full-length GHRH with a modification that slows its breakdown. It is the active ingredient of a currently FDA-approved drug for excess abdominal fat in HIV-associated lipodystrophy and has randomised adult trials, including the 2007 New England Journal of Medicine trial that supported approval. Tesamorelin costs more than sermorelin and is priced on /cost/tesamorelin; a physician choosing between them is weighing cost against adult trial data.

The strongest evidence sits in children with growth hormone deficiency. The Geref International Study Group trial in the Journal of Clinical Endocrinology and Metabolism in 1996 gave once-daily bedtime GHRH(1-29) to 110 previously untreated prepubertal children for up to a year; height velocity roughly doubled over the first six months, bone age advanced in proportion to height, fasting glucose did not change, and the drug was reported as well tolerated. A 1999 review in BioDrugs summarised the programme: sermorelin produced growth in most children with idiopathic growth hormone deficiency, though somewhat less than recombinant growth hormone did, one reason it lost the commercial argument.

A series of small 1990s trials asked whether GHRH could restore the growth hormone output that falls with age. The National Institute on Aging study (Journal of Clinical Endocrinology and Metabolism, 1992) gave GHRH(1-29) twice daily to healthy men in their late sixties for fourteen days and reported 24-hour growth hormone and IGF-1 rising to levels no longer significantly different from men in their twenties. The Johns Hopkins group (Metabolism, 1997) gave single nightly injections to eleven healthy men aged 64 to 76 for six weeks: nocturnal growth hormone rose, IGF-1 and body composition did not change. The Khorram trial (Journal of Clinical Endocrinology and Metabolism, 1997) is the longest: randomised, placebo-controlled, sixteen weeks of nightly dosing in nineteen men and women aged 55 to 71, with IGF-1 rising within two weeks, holding for twelve, then drifting back toward baseline by sixteen. A University of Washington group reported in Neurobiology of Aging in 2006 that six months of daily GHRH versus placebo in 89 healthy older adults was associated with better scores on several cognitive measures; the larger 2012 follow-on trial in Archives of Neurology used tesamorelin, a different GHRH analogue.

Sermorelin has randomised and controlled human trials, but they were run in children with growth hormone deficiency and in small groups of healthy older adults, and their endpoints were height velocity, hormone levels and laboratory measures. There is no large randomised trial of sermorelin in adults for body composition, recovery, sleep quality or "anti-aging" as an outcome. What exists for those uses is the endocrine trials above, which establish that sermorelin raises a person's own growth hormone and, with adequate dosing, IGF-1, plus prescriber experience. A 2006 review in Clinical Interventions in Aging made the case for sermorelin in adult-onset growth hormone insufficiency on exactly that basis. Adult wellness use rests on it, and compounded sermorelin is not FDA approved.

What patients most commonly describe first is sleep quality, then recovery, with body-composition change being slower and much more dependent on training and protein intake than on the vial. These are patterns described by prescribers, not trial endpoints. Response varies and nobody can promise it. If IGF-1 has not moved and nothing subjective has changed by the point your physician set, the honest conclusion is that it is not earning its place. Tolerability detail is in is sermorelin safe.

Sermorelin acetate was the active ingredient of Geref, held by EMD Serono. The diagnostic presentation, 0.05 mg base per ampoule under NDA 19-863, was approved on 28 December 1990 for evaluating the ability of the pituitary to secrete growth hormone. The treatment presentation, 0.5 mg and 1.0 mg base per vial under NDA 20-443, was approved on 26 September 1997 for idiopathic growth hormone deficiency in children with growth failure. In 2008 EMD Serono discontinued both products and requested withdrawal of both applications, and the FDA withdrew approval effective 18 June 2009. After a citizen petition filed in October 2012, the FDA published a determination in the Federal Register on 4 March 2013 that neither Geref product was withdrawn from sale for reasons of safety or effectiveness, having reviewed its own records and the post-marketing data for both. Drugs@FDA lists the applications as discontinued.

The FDA's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, does not contain sermorelin in Category 1, Category 2 or Category 3. The current Category 2 list — substances that raise significant safety concerns — contains six substances, and no GHRH analogue is among them. Sermorelin was not among the twelve peptides the FDA announced on 15 April 2026 it was removing from Category 2, and it was not on the agenda of the Pharmacy Compounding Advisory Committee's 23–24 July 2026 meeting on those peptides. The Category 2 episode that affected BPC-157, TB-500 and others never involved sermorelin.

Section 503A allows a pharmacy to compound with a bulk substance that is a component of an FDA-approved drug, is the subject of a USP or NF monograph, or appears on the FDA's 503A bulks list. Sermorelin's footing is its history as the active ingredient of an approved drug whose withdrawal the FDA itself determined was not for safety or effectiveness. On that basis 503A pharmacies have compounded it and physicians have prescribed it continuously for years, including while other peptides were restricted.

A compounded sermorelin vial is not an FDA-approved drug product, and no compounded medication ever is; there is no currently marketed FDA-approved sermorelin product in the United States. If a sales page says "FDA approved," the accurate version is "was the active ingredient of an FDA-approved drug, discontinued in 2008 for commercial reasons." See are peptides FDA approved.